A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

Inclusion Criteria: * Male or female, 18 to 75 years of age * Written informed consent * No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment * No new abnormal finding of clinical relevance at the screening evaluation. * Diagnosis of HBeAg negative, immune active, chronic HBV infection * \> 2 months of continuous treatment with daily, oral entecavir or tenofovir * Willingness to continue taking entecavir or tenofovir throughout the study. * Must use 2 effective methods of contraception (double barrier contraception or hormonal contraceptive along with a barrier contraceptive) (both male and female partners) Exclusion Criteria: * Pregnant or lactating * Acute signs of hepatitis/other infection within 4 weeks of screening * Antiviral therapy other than entecavir or tenofovir within 3 months of screening * Prior treatment with interferon in the last 3 years. * Use within the last 6 months or anticipated requirement for anticoagulants, corticosteroids, immunomodulators, or immunosuppressants. * Use of prescription medication within 14 days prior to treatment administration except: topical products without systemic absorption, statins (except rosuvastatin), hypertension medications, or hormonal contraceptives. * Depot injection or implant of any drug within 3 months prior to treatment administration, except injectable/implantable birth control. * Diagnosis of diabetes mellitus. * History of autoimmune disease especially autoimmune hepatitis. * Hu…